| 05/04/24 | 07:00:08 | 5 Apr 2024 | | Response to Share Price Movement |
| 11/03/24 | 07:00:04 | 11 Mar 2024 | | Positive Results: Midkine mRNA and STAT-6 siRNA |
| 06/02/24 | 07:00:03 | 6 Feb 2024 | | Operations Update |
| 24/11/23 | 07:00:09 | 24 Nov 2023 | | Change of Auditor |
| 06/11/23 | 07:00:13 | 6 Nov 2023 | | Significant Mesodermal Killer Cell Milestone |
| 27/09/23 | 07:00:06 | 27 Sept 2023 | | Interim Results to 30 June 2023 |
| 22/09/23 | 11:42:40 | 22 Sept 2023 | | Investor Presentation via Investor Meet Company |
| 14/08/23 | 07:00:04 | 14 Aug 2023 | | Expansion of Patent Portfolio |
| 07/08/23 | 07:00:05 | 7 Aug 2023 | | Development of New Novel siRNA Therapeutics |
| 02/08/23 | 07:00:07 | 2 Aug 2023 | | Director/PDMR Shareholding |
| 12/07/23 | 10:27:25 | 12 Jul 2023 | | Director/PDMR Shareholding |
| 29/06/23 | 10:05:01 | 29 Jun 2023 | | Results of AGM |
| 29/06/23 | 07:00:02 | 29 Jun 2023 | | AGM Statement |
| 27/06/23 | 07:00:05 | 27 Jun 2023 | | Investor Presentation via Investor Meet Company |
| 26/06/23 | 14:41:29 | 26 Jun 2023 | | Director/PDMR Shareholding |
| 26/06/23 | 10:36:26 | 26 Jun 2023 | | Director/PDMR Shareholding |
| 26/06/23 | 10:00:10 | 26 Jun 2023 | | Director/PDMR Shareholding |
| 22/06/23 | 07:00:08 | 22 Jun 2023 | | RNA Medicine Shows In Vitro Anti-Cancer Efficacy |
| 19/06/23 | 07:00:04 | 19 Jun 2023 | | Antibody Program Results & Orphan Drug Indication |
| 13/06/23 | 07:00:12 | 13 Jun 2023 | | Anti-Cancer MDK mRNA - Positive in vitro Results |
| 07/06/23 | 10:11:46 | 7 Jun 2023 | | Restoration of Trading |
| 06/06/23 | 07:00:08 | 6 Jun 2023 | | Notice of Annual General Meeting |
| 05/06/23 | 07:00:07 | 5 Jun 2023 | | Annual Report & Financial Statements - 31 Dec 2022 |
| 02/05/23 | 07:56:14 | 2 May 2023 | | Suspension of Trading Pending 2022 Annual Report |
| 02/05/23 | 07:30:02 | 2 May 2023 | | Suspension - Roquefort Therapeutics plc |
| 13/03/23 | 07:30:04 | 13 Mar 2023 | | Confirmation of No Exposure to Silicon Valley Bank |
| 08/03/23 | 07:00:06 | 8 Mar 2023 | | Creation of New Novel Family of mRNA Therapeutics |
| 06/03/23 | 07:00:02 | 6 Mar 2023 | | Formation of Scientific Advisory Board |
| 01/03/23 | 07:00:12 | 1 Mar 2023 | | Company Presentation |
| 21/02/23 | 07:00:08 | 21 Feb 2023 | | Investor Presentation |
| 20/02/23 | 07:00:03 | 20 Feb 2023 | | Randox Licence and Royalty Agreement |
| 24/01/23 | 07:00:03 | 24 Jan 2023 | | MDK Oncology Antibodies Demonstrate In-Vivo Safety |
| 18/01/23 | 08:36:18 | 18 Jan 2023 | | Holding(s) in Company |
| 16/01/23 | 07:00:06 | 16 Jan 2023 | | Appointment of Auditor |
| 09/01/23 | 07:00:01 | 9 Jan 2023 | | Operations Update |
| 05/12/22 | 08:07:52 | 5 Dec 2022 | | Presentation of Midkine Oligonucleotide Program |
| 01/12/22 | 14:00:06 | 1 Dec 2022 | | Resignation of Auditor |
| 25/10/22 | 07:00:06 | 25 Oct 2022 | | Midkine Antibody Program - Festival of Biologics |
| 11/10/22 | 07:00:17 | 11 Oct 2022 | | ROQ Presents Study Results at the ESGCT Conference |
| 28/09/22 | 07:00:12 | 28 Sept 2022 | | Director/PDMR Shareholding |
| 26/09/22 | 14:30:08 | 26 Sept 2022 | | Director/PDMR Shareholding |
| 23/09/22 | 07:00:06 | 23 Sept 2022 | | Interim Results to 30 June 2022 |
| 16/09/22 | 08:00:04 | 16 Sept 2022 | | Investor Presentation |
| 16/09/22 | 07:01:01 | 16 Sept 2022 | | Board and Management Appointments |
| 16/09/22 | 07:00:04 | 16 Sept 2022 | | Acquisition Completion, Admission & Voting Rights |
| 15/09/22 | 12:26:17 | 15 Sept 2022 | | Notice of Admission |
| 13/09/22 | 11:08:19 | 13 Sept 2022 | | Publication of Prospectus |
| 11/08/22 | 07:00:12 | 11 Aug 2022 | | Pre-clinical Program & Transaction Update |
| 20/07/22 | 07:00:09 | 20 Jul 2022 | | Appointment of Joint Broker |
| 15/07/22 | 07:00:05 | 15 Jul 2022 | | Commencement of Trading on US OTCQB Venture Market |
